111 related articles for article (PubMed ID: 4027997)
1. Effect of intravesical Bacillus Calmette-Guérin on detection of a urothelial differentiation antigen in exfoliated cells of carcinoma in situ of the human urinary bladder.
Huffman JL; Fradet Y; Cordon-Cardo C; Herr HW; Pinsky CM; Oettgen HF; Old LJ; Whitmore WF; Melamed MR
Cancer Res; 1985 Oct; 45(10):5201-4. PubMed ID: 4027997
[TBL] [Abstract][Full Text] [Related]
2. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
4. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
5. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
Chang SG; Lee SJ; Huh JS; Lee JH
Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
[TBL] [Abstract][Full Text] [Related]
6. Intravesical instillations with bacillus calmette-guérin for the treatment of carcinoma in situ involving prostatic ducts.
Palou Redorta J; Schatteman P; Huguet Pérez J; Segarra Tomás J; Rosales Bordes A; Algaba F; Villavicencio Mavrich H
Eur Urol; 2006 May; 49(5):834-8; discussion 838. PubMed ID: 16426729
[TBL] [Abstract][Full Text] [Related]
7. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
[TBL] [Abstract][Full Text] [Related]
8. Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided?
Smith PJ; Lotan Y; Raj GV; Sagalowsky AI; Margulis V
Cytopathology; 2014 Apr; 25(2):108-11. PubMed ID: 23551700
[TBL] [Abstract][Full Text] [Related]
9. [Is second course intravesical Bacillus Calmette-Guerin therapy for recurrent carcinoma in situ of the bladder useful?].
Yamada Y; Hara I; Kumano M; Furukawa J; Yamanaka K; Kamidono S
Hinyokika Kiyo; 2005 Aug; 51(8):539-43. PubMed ID: 16164270
[TBL] [Abstract][Full Text] [Related]
10. Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics.
Fradet Y; Cordon-Cardo C; Whitmore WF; Melamed MR; Old LJ
Cancer Res; 1986 Oct; 46(10):5183-8. PubMed ID: 3756873
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
Ovesen H; Horn T; Steven K
J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
[TBL] [Abstract][Full Text] [Related]
12. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
13. Discrepancies between cytology, cystoscopy and biopsy in bladder cancer detection after Bacille Calmette-Guerin intravesical therapy.
Hara T; Takahashi M; Gondo T; Nagao K; Ohmi C; Sakano S; Naito K; Matsuyama H
Int J Urol; 2009 Feb; 16(2):192-5. PubMed ID: 19054166
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ of bladder].
Uekado Y; Kohjimoto Y; Iba A; Kikkawa K; Shintani Y; Shinka T
Hinyokika Kiyo; 2006 Jun; 52(6):439-44. PubMed ID: 16848357
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guerin induces long-term local formation of nitric oxide in the bladder via the induction of nitric oxide synthase activity in urothelial cells.
Morcos E; Jansson OT; Adolfsson J; Ehrén I; Wiklund NP
J Urol; 2001 Feb; 165(2):678-82. PubMed ID: 11176457
[TBL] [Abstract][Full Text] [Related]
17. [Bacillus Calmette-Guerin intravesical instillation treatment for carcinoma in situ of the bladder. Gifu BCG Instillation Therapy Research Group].
Nishino Y; Yasuda M; Yokoi S; Ehara H; Yamamoto N; Takahashi Y; Ishihara S; Deguchi T; Kawada Y; Takeda A; Sakai S; Takeuchi T; Taniguchi M; Minoshima K; Hamamoto Y; Kanimoto Y; Nakano M; Fujihiro S; Nezasa S; Matsuda T; Nagatani Y; Maeda S; Tamaki M; Saito A; Komeda H
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1869-73. PubMed ID: 10560414
[TBL] [Abstract][Full Text] [Related]
18. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
19. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
20. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
